Invesco Ltd. Has $14.72 Million Stock Holdings in Emergent BioSolutions Inc. (NYSE:EBS)

Invesco Ltd. boosted its position in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 70.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,539,907 shares of the biopharmaceutical company’s stock after purchasing an additional 638,995 shares during the quarter. Invesco Ltd. owned 2.84% of Emergent BioSolutions worth $14,722,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of EBS. Stifel Financial Corp acquired a new position in shares of Emergent BioSolutions in the 3rd quarter valued at $96,000. State Street Corp lifted its holdings in Emergent BioSolutions by 864.7% during the third quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock worth $15,960,000 after acquiring an additional 1,713,200 shares in the last quarter. Barclays PLC grew its stake in Emergent BioSolutions by 361.6% in the third quarter. Barclays PLC now owns 39,308 shares of the biopharmaceutical company’s stock valued at $329,000 after acquiring an additional 30,792 shares during the period. Geode Capital Management LLC increased its holdings in shares of Emergent BioSolutions by 4.6% in the third quarter. Geode Capital Management LLC now owns 581,958 shares of the biopharmaceutical company’s stock worth $4,861,000 after acquiring an additional 25,776 shares in the last quarter. Finally, Oak Hill Advisors LP acquired a new stake in shares of Emergent BioSolutions during the third quarter worth about $9,296,000. Institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Trading Down 0.1 %

NYSE EBS opened at $4.62 on Monday. The stock has a market capitalization of $250.77 million, a price-to-earnings ratio of -1.13 and a beta of 2.14. Emergent BioSolutions Inc. has a 52 week low of $1.82 and a 52 week high of $15.10. The stock’s 50 day moving average price is $5.97 and its two-hundred day moving average price is $8.31. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88.

Emergent BioSolutions (NYSE:EBS) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.35) by $0.40. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. The business had revenue of $194.70 million during the quarter, compared to analysts’ expectations of $254.67 million. During the same quarter in the prior year, the company posted ($0.77) earnings per share. As a group, analysts anticipate that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Emergent BioSolutions announced that its Board of Directors has initiated a stock repurchase plan on Monday, March 31st that allows the company to buyback $50.00 million in shares. This buyback authorization allows the biopharmaceutical company to buy up to 19% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on EBS. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Emergent BioSolutions in a research report on Tuesday, April 1st. StockNews.com cut shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Wednesday, March 5th.

Insider Transactions at Emergent BioSolutions

In other news, Director Neal Franklin Fowler sold 35,000 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total value of $204,050.00. Following the sale, the director now directly owns 101,100 shares of the company’s stock, valued at approximately $589,413. This represents a 25.72 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 3.20% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.